July 23, 2021 – The U.S. FDA has approved an expanded indication for Bydureon BCise (exenatide extended release), manufactured by AstraZeneca. Initially FDA approved
July 23, 2021 – Bristol Myers Squibb has voluntarily withdrawn an indication for Opdivo® (nivolumab) to be used as a single agent to treat patients who have hepatocellular
July 23, 2021 – The U.S. FDA has approved a new indication for Drizalma SprinkleTM (duloxetine) delayed-release oral capsules, manufactured by Sun Pharmaceutical. The capsules are